EASL Endorsed Consortia
About
EASL Endorsed Consortia are independent, collaborative research networks of clinical and biomedical centres dedicated to advancing hepatology.
Through endorsement, EASL recognises the scientific merit and strategic value of each consortium, supporting their visibility and ability to engage funders, industry, and the wider hepatology community — while each consortium retains full autonomy over its own governance, funding, and research activities.
Aim
- Build critical mass around specific liver disease topics by bringing together multidisciplinary expertise from across Europe and beyond
- Foster collaboration between basic and clinical research to accelerate translation of scientific discovery into patient benefit
- Identify emerging research priorities and create synergies between member groups, as well as with industry and other external partners
- Design and coordinate multi-annual research programmes, including calls for research proposals open to member centres on a voluntary basis
- Support fundraising from public agencies, foundations, and industry to sustain approved research activities
- Stimulate the development of new research groups and create pathways for young investigators to enter and grow within the field
EASL Baveno Consortium
The mission of the Baveno Cooperation is to advance knowledge in the field of advanced chronic liver disease (ACLD) and portal hypertension (PH) with the ultimate goal to improve outcomes of patients with ACLD and PH.
Current activities
Research focus
Advanced chronic liver disease (ACLD), traditionally termed cirrhosis. Portal Hypertension, particularly clinically significant portal hypertension (CSPH) and its complications.
Current research projects
The EASL BAVENO Consortium has several active research projects and studies that are summarised on the BAVENO website (free registration as a member required).
Recent publications
Baveno consensus reports with key recommendations for clinical management of patients with advanced chronic liver disease (ACLD) and clinically significant portal hypertension (CSPH).
Membership & Participation
Consortium membership
While operating as an official EASL consortium, Baveno has a global membership with currently (April 2026) 307 members from 83 countries.
How to join?
The Baveno Cooperation is open to new members that are active in the field of advanced chronic liver disease (ACLD) and portal hypertension (PH).
Membership is free but requires approval at the bi-annual general assemblies.
Opportunities for Young Investigators
The Baveno Cooperation offers various opportunities for Young Investigators
- Participation in the Baveno working groups/committees, e.g. the communication committee
- Abstract prices for YI at the Baveno consensus workshops
- Reduced registration fee for YI to participate in the Baveno consensus workshops
Governance & Contact
Chair
Vice-Chair
Secretary
Vice-Secretary
European Network for the Study of Cholangiocarcinoma
European Network for the Study of Cholangiocarcinoma (ENS-CCA) is a network of active researchers with a broad interest in CCA, and biliary tract cancer in general, which have significantly contributed to the study into the pathophysiology of the biliary tree and development/onset of CCA, pursuing basic, translational and clinical research in an effort to identify treatment options with successful outcome for this type of cancer. For years, our laboratories have generated, together with our colleagues, many of the key advances in this field. ENS-CCA include research groups located in 15 European countries with interest in CCA from Basic, Translational and Clinical research.
Current activities
Research focus
Advanced chronic liver disease (ACLD), traditionally termed cirrhosis. Portal Hypertension, particularly clinically significant portal hypertension (CSPH) and its complications.
Current research projects
The EASL BAVENO Consortium has several active research projects and studies that are summarised on the BAVENO website (free registration as a member required).
Recent publications
Baveno consensus reports with key recommendations for clinical management of patients with advanced chronic liver disease (ACLD) and clinically significant portal hypertension (CSPH).
Membership & Participation
Consortium membership
While operating as an official EASL consortium, Baveno has a global membership with currently (April 2026) 307 members from 83 countries.
How to join?
The Baveno Cooperation is open to new members that are active in the field of advanced chronic liver disease (ACLD) and portal hypertension (PH).
Membership is free but requires approval at the bi-annual general assemblies.
Opportunities for Young Investigators
The Baveno Cooperation offers various opportunities for Young Investigators
- Participation in the Baveno working groups/committees, e.g. the communication committee
- Abstract prices for YI at the Baveno consensus workshops
- Reduced registration fee for YI to participate in the Baveno consensus workshops
Governance & Contact
Coordinator
EASL-CLIF Consortium
The EASL-CLIF Consortium, coordinated by the European Foundation for the Study of Chronic Liver Failure (EF CLIF) — a non-profit research organization that provides operational support and infrastructure for the Consortium — brings together 120 hospitals across Europe to conduct research on liver disease and generate evidence that improves patient care and clinical guidelines. Through large collaborative studies and new initiatives, the network also trains the next generation of researchers and provides unique career development opportunities for emerging leaders in the field.
Current activities
Research focus
Complications of cirrhosis and acute-on-chronic liver failure (ACLF)
Current research projects
CHANCE study
For more information: https://efclif.com/projects/chance-liver-transplantation-in-patients-with-cirrhosis-and-severe-acute-on-chronic-liver-failure-indications-and-outcomes/
Milestones
The PREDICT study – a prospective investigation of new events that occurred by 3 months after admission for acute decompensation of cirrhosis without ACLF – revealed three distinct trajectories of acute decompensation of cirrhosis, including pre-ACLF (defining patients who are frequently readmitted and eventually develop ACLF within days or weeks after admission and frequently die), unstable decompensated cirrhosis (defining patients who develop complications related to portal hypertension but not ACLF and die less often that pre-ACLF patients) and stable decompensated cirrhosis (defining patients who are discharged rapidly and remain free of readmission during the 3-month follow-up).
Most relevant publications
- Maladaptive emergency granulopoiesis predicts poor outcomes in patients hospitalized with decompensated cirrhosis.
J Hepatol. 2026 Apr;84(4):749-765. doi: 10.1016/j.jhep.2025.11.012. Epub 2025 Nov 26.
Aguilar F, Lozano JJ, Clària J, Reinartz Groba SN, Richter M, Jiménez-Gracia L, Grange P, Jolly A, Praktiknjo M, Sánchez-Garrido C, Uson Raposo EM, García-Torre B, Laleman W, Gómez-Cabrero D, Palomino-Echeverria S, Iglesias EH, Farias AQ, Marciano S, Caraceni P, Trebicka J, Cerutti A, Arroyo V, Heyn H, Nieto JC, Soehnlein O, Rautou PE, Moreau R; DECISION Consortium.
- PREDICT study and ACLARA study. Gene score to quantify systemic inflammation in patients with acutely decompensated cirrhosis.
Gut. 2025 Jul 7;74(8):1293-1307. doi: 10.1136/gutjnl-2024-333876. Erratum in: Gut. 2025 Aug 7;74(9):e18. doi: 10.1136/gutjnl-2024-333876corr1.
Trebicka J, Aguilar F, Queiroz Farias A, Lozano JJ, Sánchez-Garrido C, Usón-Raposo E, de la Peña-Ramirez C, Sidorova J, Curto-Vilalta A, Sierra-Casas P, Momoyo Zitelli P, Papp M, Pereira G, Caraceni P, Goncalves LL, Alessandria C, Torre A, Laleman W, Gadano A, Piano S, Mattos AZ, Gu W, Brol MJ, Schierwagen R, Uschner FE, Fischer J, Mendes LSC, Vargas V, Alvares-da-Silva MR, Mookerjee R, Bittencourt PL, Benitez C, Albillos A, Couto C, Mendizabal M, Bañares R, Toledo CL, Mazo DF, Janicko M, Castillo-Barradas M, Padilla Machaca PM, Gatti P, Miranda AZ, Malé-Velázquez R, Zipprich A, Castro-Lyra A, Gustot T, Bernal W, Gerbes AL, Jalan R, Fernández J, Angeli P, Carrilho FJ, Claria J, Moreau R, Arroyo V;
Genetic Ancestry, Race, and Severity of Acutely Decompensated Cirrhosis in Latin America. Gastroenterology.
2023 Sep;165(3):696-716. doi: 10.1053/j.gastro.2023.05.033. Epub 2023 May 30.
Farias AQ, Curto Vilalta A, Momoyo Zitelli P, Pereira G, Goncalves LL, Torre A, Diaz JM, Gadano AC, Mattos AZ, Mendes LSC, Alvares-da-Silva MR, Bittencourt PL, Benitez C, Couto CA, Mendizabal M, Toledo CL, Mazo DFC, Castillo Barradas M, Uson Raposo EM, Padilla-Machaca PM, Zarela Lozano Miranda A, Malé-Velázquez R, Castro Lyra A, Dávalos-Moscol MB, Pérez Hernández JL, Ximenes RO, Faria Silva G, Beltrán-Galvis OA, González Huezo MS, Bessone F, Rocha TDS, Fassio E, Terra C, Marín JI, Sierra Casas P, de la Peña-Ramirez C, Aguilar Parera F, Fernandes F, da Penha Zago-Gomes M, Méndez-Guerrero O, Marciano S, Mattos AA, Oliveira JC, Guerreiro GTS, Codes L, Arrese M, Nardelli MJ, Silva MO, Palma-Fernandez R, Alcantara C, Sánchez Garrido C, Trebicka J, Gustot T, Fernández J, Clària J, Jalan R, Angeli P, Arroyo V, Moreau R, Carrilho FJ; ACLARA Study Collaborators.
- Sympathetic nervous activation, mitochondrial dysfunction and outcome in acutely decompensated cirrhosis: the metabolomic prognostic models (CLIF-C MET).
Gut. 2023 Aug;72(8):1581-1591. doi: 10.1136/gutjnl-2022-328708. Epub 2023 Feb 14. Erratum in: Gut. 2023 Nov;72(11):e4. doi: 10.1136/gutjnl-2022-328708corr1.
Weiss E, de la Peña-Ramirez C, Aguilar F, Lozano JJ, Sánchez-Garrido C, Sierra P, Martin PI, Diaz JM, Fenaille F, Castelli FA, Gustot T, Laleman W, Albillos A, Alessandria C, Domenicali M, Caraceni P, Piano S, Saliba F, Zeuzem S, Gerbes AL, Wendon JA, Jansen C, Gu W, Papp M, Mookerjee R, Gambino CG, Jiménez C, Giovo I, Zaccherini G, Merli M, Putignano A, Uschner FE, Berg T, Bruns T, Trautwein C, Zipprich A, Bañares R, Presa J, Genesca J, Vargas V, Fernández J, Bernardi M, Angeli P, Jalan R, Claria J, Junot C, Moreau R, Trebicka J, Arroyo V.
Ongoing and upcoming studies
Ongoing study – Accepting centers:
CHANCE study – for more information: https://efclif.com/projects/chance-liver-transplantation-in-patients-with-cirrhosis-and-severe-acute-on-chronic-liver-failure-indications-and-outcomes/
Upcoming study – Call for participating centers:
A new study (MAPS), developed in collaboration with the EASL-Baveno Consortium, will soon open a call for participating centers.
Membership & Participation
Consortium membership
120 hospitals across 29 Europe.
How to join?
Please refer to the EASL-CLIF Consortium page on the EF CLIF website for details on how to become a member.
For more information: https://efclif.com/about-us/our-network/easl-clif-consortium/
Opportunities for Young Investigators
Education and Training
Master’s Programme in Research in Hepatology
For more information: https://edu.efclif.com/
Governance & Contact
Chair
Vice-Chair
Please see full EASL-CLIF Consortium Steering Committee members at https://efclif.com/about-us/our-organization/committees/easl-clif-consortium-steering-committee/
Contact
For more information: https://efclif.com/about-us/our-network/easl-clif-consortium/
EASL Consortium for Regenerative Hepatology
The EASL Consortium for Regenerative Hepatology is aimed at the delivery of bioengineered tissues and associated biotechnologies for regenerative hepatology.
The Consortium is a multidisciplinary European-based organisation including individual research groups or established centers willing to join efforts to achieve common goals and fosters the acquisition of financial resources to support the activity of the Consortium.
Current activities
Research focus
Advanced chronic liver disease (ACLD), traditionally termed cirrhosis. Portal Hypertension, particularly clinically significant portal hypertension (CSPH) and its complications.
Current research projects
The EASL BAVENO Consortium has several active research projects and studies that are summarised on the BAVENO website (free registration as a member required).
Recent publications
Baveno consensus reports with key recommendations for clinical management of patients with advanced chronic liver disease (ACLD) and clinically significant portal hypertension (CSPH).
Membership & Participation
Consortium membership
While operating as an official EASL consortium, Baveno has a global membership with currently (April 2026) 307 members from 83 countries.
How to join?
The Baveno Cooperation is open to new members that are active in the field of advanced chronic liver disease (ACLD) and portal hypertension (PH).
Membership is free but requires approval at the bi-annual general assemblies.
Opportunities for Young Investigators
The Baveno Cooperation offers various opportunities for Young Investigators
- Participation in the Baveno working groups/committees, e.g. the communication committee
- Abstract prices for YI at the Baveno consensus workshops
- Reduced registration fee for YI to participate in the Baveno consensus workshops
Governance & Contact
EASL DHILI Consortium
The EASL DHILI Consortium is a multidisciplinary network of clinicians, scientists, patients, industry partners, and regulators, all with an interest in the study of Drug and Herbal & Dietary Supplement-induced Liver Injury.
Current activities
Research focus
Advanced chronic liver disease (ACLD), traditionally termed cirrhosis. Portal Hypertension, particularly clinically significant portal hypertension (CSPH) and its complications.
Current research projects
The EASL BAVENO Consortium has several active research projects and studies that are summarised on the BAVENO website (free registration as a member required).
Recent publications
Baveno consensus reports with key recommendations for clinical management of patients with advanced chronic liver disease (ACLD) and clinically significant portal hypertension (CSPH).
Membership & Participation
Consortium membership
While operating as an official EASL consortium, Baveno has a global membership with currently (April 2026) 307 members from 83 countries.
How to join?
The Baveno Cooperation is open to new members that are active in the field of advanced chronic liver disease (ACLD) and portal hypertension (PH).
Membership is free but requires approval at the bi-annual general assemblies.
Opportunities for Young Investigators
The Baveno Cooperation offers various opportunities for Young Investigators
- Participation in the Baveno working groups/committees, e.g. the communication committee
- Abstract prices for YI at the Baveno consensus workshops
- Reduced registration fee for YI to participate in the Baveno consensus workshops
Governance & Contact
SALVE Consortium
SALVE (Study of Alcohol-Related Liver Disease in Europe) is a multi-centre research consortium uniting leading hepatologists, pathologists, and clinical researchers from across Europe.
Our mission is to improve outcomes for patients with alcohol-related liver disease through collaborative research into natural history, pathogenesis, biomarker development, and novel therapeutic approaches. By pooling clinical data and expertise across borders, we aim to accelerate discoveries that translate into better patient care.
Current activities
Research focus
The main focus of the consortium is to better understand the natural history of alcohol-related liver disease. The SALVE histopathology group aims to better characterise histological characteristics and prognosis markers in alcohol-related liver disease
Current research projects
- Large prospective multicenter database in patients with ALD
- SALVE histopathology group: histological markers of steroid response in severe alcohol-related hepatitis
- Non-invasive biomarkers of liver fibrosis in subjects with high risk of alcohol-related liver disease: a multicenter study
Milestones
- Validation of NIAAAm-CRP to predict alcohol-associated steatohepatitis on liver histology. Stauber RE, Ratou PE, Stefanescu H, et al. JHEP Rep 2024
- Development and prognostic relevance of a histologic grading and staging system for alcohol-related liver disease. Lackner C, Stauber RE, Davies S et al. J Hepatol 2021
- Dual aetiology fatty liver disease : A recently proposed term associated with potential pitfalls. Moreno C, Sheron N, Tiniakos D, et al. J Hepatol 2021
Most relevant publications
- Validation of NIAAAm-CRP to predict alcohol-associated steatohepatitis on liver histology. Stauber RE, Ratou PE, Stefanescu H, et al. JHEP Rep 2024
- Development and prognostic relevance of a histologic grading and staging system for alcohol-related liver disease. Lackner C, Stauber RE, Davies S et al. J Hepatol 2021
- Dual aetiology fatty liver disease : A recently proposed term associated with potential pitfalls. Moreno C, Sheron N, Tiniakos D, et al. J Hepatol 2021
Upcoming studies
- Large prospective multicenter database in patients with ALD: the study is open for every center willing to participate and with an interest in ALD
- Non-invasive biomarkers of liver fibrosis in subjects with high risk of alcohol-related liver disease: a multicenter study: still open for additional centers
Membership & Participation
Consortium membership
Currently there are 60 individual members, coming from 15 countries and representing ~ 23 insitutions.
How to join?
The SALVE Consortium is open. If you are interested in joining, please send a short letter of intent and a short CV to the SALVE Secretary. Shortly the process will be available via the new website
Opportunities for Young Investigators
Young Investigators are present in the consortium and are welcome to join.
Governance & Contact
VALDIG Consortium
VALDIG (Vascular Liver Disease Group) is a independent network of researchers with a common interest in Vascular Liver Diseases.
The aim of this network is to foster research in this field.
All VALDIG centres are connected by one database, which allows for the coordination of joint research projects.
In addition, VALDIG is supporting the establishment of new research groups to provide young researchers with the opportunity for interaction and knowledge building.
Current activities
Research focus
The main focus of the consortium is to better understand the natural history of alcohol-related liver disease. The SALVE histopathology group aims to better characterise histological characteristics and prognosis markers in alcohol-related liver disease
Current research projects
- Large prospective multicenter database in patients with ALD
- SALVE histopathology group: histological markers of steroid response in severe alcohol-related hepatitis
- Non-invasive biomarkers of liver fibrosis in subjects with high risk of alcohol-related liver disease: a multicenter study
Milestones
- Validation of NIAAAm-CRP to predict alcohol-associated steatohepatitis on liver histology. Stauber RE, Ratou PE, Stefanescu H, et al. JHEP Rep 2024
- Development and prognostic relevance of a histologic grading and staging system for alcohol-related liver disease. Lackner C, Stauber RE, Davies S et al. J Hepatol 2021
- Dual aetiology fatty liver disease : A recently proposed term associated with potential pitfalls. Moreno C, Sheron N, Tiniakos D, et al. J Hepatol 2021
Most relevant publications
- Validation of NIAAAm-CRP to predict alcohol-associated steatohepatitis on liver histology. Stauber RE, Ratou PE, Stefanescu H, et al. JHEP Rep 2024
- Development and prognostic relevance of a histologic grading and staging system for alcohol-related liver disease. Lackner C, Stauber RE, Davies S et al. J Hepatol 2021
- Dual aetiology fatty liver disease : A recently proposed term associated with potential pitfalls. Moreno C, Sheron N, Tiniakos D, et al. J Hepatol 2021
Upcoming studies
- Large prospective multicenter database in patients with ALD: the study is open for every center willing to participate and with an interest in ALD
- Non-invasive biomarkers of liver fibrosis in subjects with high risk of alcohol-related liver disease: a multicenter study: still open for additional centers
Membership & Participation
Consortium membership
Currently there are 60 individual members, coming from 15 countries and representing ~ 23 insitutions.
How to join?
Please refer to the EASL-VALDIG Consortium website on how to become a member.
For more information: https://www.valdig.eu/become-member/
Opportunities for Young Investigators
Young Investigators are present in the consortium and are welcome to join.
